Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics
WIREs Nanomedicine and Nanobiotechnology · 2024-11 · 16 (6)
DOI: 10.1002/wnan.2020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, online erschienen am 11.12.2024. Verfasst von Wutong Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience and Technology, Beijing, China. Hauptthemen laut MEDLINE: Neoplasms, Proteolysis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 84 Literaturangaben.
Abstract (Originalsprache)
Targeted protein degradation (TPD) represents an innovative therapeutic strategy that has garnered considerable attention from both academic and industrial sectors due to its promising developmental prospects. Approximately 85% of human proteins are implicated in disease pathogenesis, and the FDA has approved around 400 drugs targeting these disease‐related proteins, predominantly enzymes, transcription factors, and non‐enzymatic proteins. However, existing therapeutic modalities fail to address certain “high‐value” targets, such as c‐Myc and Ras. The emergence of proteolysis‐targeting chimeras (PROTAC) technology has introduced TPD into a new realm. The capability to target non‐druggable sites has expanded the therapeutic horizon of protein‐based drugs, although challenges related to bioavailability, safety, and adverse side effects have constrained their clinical progression. Nano‐delivery systems and emerging TPD modalities, such as molecular glues, lysosome‐targeted chimeras (LYTACs), autophagy system compounds (ATTEC), and antibody PROTAC (AbTACs), have mitigated some of these limitations. This paper reviews the latest advancements in TPD, highlighting their applications and benefits in cancer therapy, and concludes with a forward‐looking perspective on the future development of this field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience and Technology, Beijing, China.
- Zhangjiakou First Hospital, Zhangjiakou, China.
- The Second Affiliated Hospital of Hebei North University, Zhangjiakou, China.
ORCID-Profile: Hai Wang
Zitieren
APA
Zhao, W., Jiang, Y., Li, X., & Wang, H. (2024). Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics. WIREs Nanomedicine and Nanobiotechnology, 16(6). https://doi.org/10.1002/wnan.2020
Vancouver
Zhao W, Jiang Y, Li X, Wang H. Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics. WIREs Nanomedicine and Nanobiotechnology. 2024;16(6). doi:10.1002/wnan.2020
BibTeX
@article{Zhao2024,
author = {Zhao, Wutong and Jiang, Yongbin and Li, Xiufen and Wang, Hai},
title = {Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics},
journal = {WIREs Nanomedicine and Nanobiotechnology},
year = {2024},
volume = {16},
number = {6},
doi = {10.1002/wnan.2020}
}
EUVIMED